Prognostic value of demographic variables, clinical characteristics and findings from coronary angiogram and cardiovascular magnetic resonance imaging in the univariate analysis
| Primary endpoint* | Secondary endpoint† | |||
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Demographic variables: | ||||
| Age (years) | 1.05 (1.01 to 1.09) | 0.007 | 1.04 (0.98 to 1.10) | 0.23 |
| Sex (M) | 0.79 (0.27 to 2.30) | 0.67 | 1.67 (0.45 to 6.22) | 0.45 |
| Clinical characteristics: | ||||
| Hypertension (y/n) | 0.98 (0.43 to 2.25) | 0.97 | 1.20 (0.32 to 4.43) | 0.79 |
| Diabetes (y/n) | 0.97 (0.39 to 2.40) | 0.94 | 1.74 (0.52 to 5.80) | 0.37 |
| Hypercholesterolaemia (y/n) | 1.51 (0.61 to 3.77) | 0.37 | 0.94 (0.28 to 3.15) | 0.92 |
| Current smoker (y/n) | 0.86 (0.39 to 1.92) | 0.72 | 1.68 (0.54 to 5.23) | 0.37 |
| History of MI (y/n) | 1.44 (0.67 to 3.11) | 0.35 | 2.09 (0.67 to 6.47) | 0.20 |
| Presentation with ACS (y/n) | 0.74 (0.17 to 3.14) | 0.68 | 1.98 (0.42 to 9.35) | 0.39 |
| PCI cohort (y/n) | 0.83 (0.37 to 1.87) | 0.66 | 0.38 (0.10 to 1.50) | 0.17 |
| Troponin before revascularisation (μg/l) | 0.47 (0.08 to 2.73) | 0.40 | 1.0 (0.19 to 5.19) | 1.0 |
| Troponin after revascularisation (μg/l) | 1.02 (0.97 to 1.07) | 0.38 | 0.98 (0.88 to 1.09) | 0.72 |
| PMI | 2.23 (0.91 to 5.93) | 0.08 | 2.97 (0.62 to 14.21) | 0.17 |
| Troponin >0.2 μg/l‡ | 2.09 (0.62 to 7.05) | 0.24 | 2.66 (0.34 to 21.06) | 0.36 |
| Medication (y/n): | ||||
| Anti-platelets | –¶ | 1.00 | –¶ | 1.00 |
| Statin | –¶ | 1.00 | –¶ | 1.00 |
| ACE inhibitor | 1.72 (0.39 to 0.72) | 0.47 | 0.72 (0.07 to 7.14) | 0.78 |
| β-blocker | 0.90 (0.34 to 2.41) | 0.84 | 1.00 | |
| Calcium channel blocker | 1.64 (0.63 to 4.24) | 0.31 | 6.90 (0.71 to 67.02) | 0.10 |
| Coronary angiogram: | ||||
| Number of diseased vessels | 1.31 (0.80 to 2.14) | 0.28 | 1.51(0.70 to 3.31) | 0.29 |
| Presence of TCO (y/n) | 1.39 (0.52 to 3.69) | 0.51 | 1.25 (0.27 to 5.75) | 0.78 |
| CMR before revascularisation: | ||||
| LVEF (%) | 0.99 (0.95 to 1.02) | 0.37 | 1.01 (0.96 to 1.06) | 0.70 |
| LVEDVI (ml) | 1.02 (1.00 to 1.04) | 0.03 | 1.01 (0.98 to 1.04) | 0.30 |
| LVESVI (ml) | 1.02 (1.00 to 1.04) | 0.03 | 1.01 (0.98 to 1.05) | 0.54 |
| SVI (ml) | 1.01 (0.97 to 1.05) | 0.61 | 1.02 (0.96 to 1.08) | 0.54 |
| LV mass index (g) | 1.01 (0.99 to 1.04) | 0.31 | 1.03 (0.99 to 1.07) | 0.20 |
| LV mass absolute (g) | 1.01 (1.00 to 1.02) | 0.17 | 1.01 (1.00 to 1.03) | 0.15 |
| Hyperenhancement (g) | 1.02 (0.99 to 1.05) | 0.21 | 1.02 (0.98 to 1.07) | 0.30 |
| Presence of hyperenhancement (y/n) | 1.33 (0.60 to 2.93) | 0.48 | 1.66 (0.50 to 5.51) | 0.41 |
| CMR after revascularisation: | ||||
| LVEF (%) | 0.97 (0.94 to 1.00) | 0.03 | 1.01 (0.95 to 1.06) | 0.84 |
| Change in LVEF pre/post (%) | 0.96 (0.92 to 1.00) | 0.06 | 0.99 (0.92 to 1.06) | 0.75 |
| LVEDVI (ml) | 1.02 (1.00 to 1.03) | 0.13 | 0.99 (0.96 to 1.03) | 0.74 |
| LVESVI (ml) | 1.02 (1.00 to 1.04) | 0.01 | 1.00 (0.96 to 1.04) | 0.96 |
| SVI (ml) | 0.98 (0.94 to 1.02) | 0.31 | 0.98 (0.92 to 1.04) | 0.46 |
| LV mass index (g) | 1.01 (0.98 to 1.03) | 0.72 | 1.00 (0.96 to 1.05) | 0.85 |
| LV mass absolute (g) | 1.00 (0.99 to 1.02) | 0.50 | 1.00 (0.98 to 1.02) | 0.88 |
| Hyperenhancement (g) | 1.03 (1.00 to 1.06) | 0.03 | 1.03 (0.99 to 1.07) | 0.10 |
| Presence of hyperenhancement (y/n) | 2.46 (0.93 to 6.50) | 0.07 | 5.95 (0.77 to 46.09) | 0.09 |
| New hyperenhancement (g) | 1.12 (1.05 to 1.19) | <0.001 | 1.10 (1.00 to 1.22) | 0.05 |
| Presence of new hyperenhancement (y/n) | 3.05 (1.42 to 6.59) | 0.004 | 2.99 (0.95 to 9.44) | 0.06 |
*Primary endpoint defined as death, non-fatal myocardial infarction, prolonged ventricular arrhythmia or admission for angina or heart failure.
†Secondary endpoint defined as death, non-fatal myocardial infarction or prolonged ventricular arrhythmia.
‡0.2 μg/l equals the 99th centile of the lower limit of quantification.
¶Hazard ratios (HR) and confidence intervals (CI) could not be estimated as only five patients were not on a statin and seven patients were not on aspirin and none of these patients had an endpoint qualifying event.
Abbreviations as for table 1.